Dr. Karyakina’s research has a particular focus on multidisciplinary studies regarding potential adverse effects (such as cancer, mutations, endocrine disruption, neurotoxicity and reproductive toxicity) of pharmaceuticals, hazardous chemicals, essential and toxic metals. Dr. Karyakina has also been involved in the derivation of biomonitoring equivalents for toxic metals (e.g., lithium, tellurium, titanium dioxide, lanthanum); the development of adverse outcome pathways for the evaluation of carcinogenicity of metals and oxides (TiO2, Al2O3); the development of toxicity profiles for several chemicals on Health Canada’s Domestic Substances List (DSL); evaluation of hazardous properties, classification and labeling of toxic chemical compounds for the European Union REACH program (aluminium, manganese, cooper); and derivation of health-based Derived No Effect Levels (DNELs) for workers and the general population.
Dr. Karyakina has extensive experience in conducting human health risk assessments for hazards present in air, water, food and consumer products such as pesticides, chemicals, and pharmaceuticals. Her work has included detailed toxicological reviews; structured systematic reviews; literature reviews and evidence syntheses. Her work has been published in a range of scientific journals such as Critical Reviews in Toxicology and Neurotoxicology.